礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LLY 礼来

交易中 04-24 13:53:07 EDT

736.09

-9.60

-1.29%

最高752.64	最低728.79	成交量118.28万
今开752.64	昨收745.69	日振幅3.20%
总市值6,998亿	流通市值6,978亿	总股本9.51亿
成交额8.69亿	换手率0.12%	流通股本9.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":736.09,"timestamp":1713981185940,"preClose":745.69,"halted":0,"volume":1182840,"delay":0,"floatShares":948000000,"shares":950766100,"eps":5.521359,"marketStatus":"交易中","marketStatusCode":2,"change":-9.6,"latestTime":"04-24 13:53:07 EDT","open":752.64,"high":752.64,"low":728.785,"amount":869306375.46,"amplitude":0.031991,"askPrice":736.53,"askSize":1,"bidPrice":736.15,"bidSize":1,"shortable":3,"etf":0,"ttmEps":5.521359,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713988800000},"adr":0,"listingDate":102488400000,"adjPreClose":745.69,"adrRate":0,"dividendRate":0.006141,"preHourTrading":{"tag":"盘前","latestPrice":753.96,"preClose":745.69,"latestTime":"09:29 EDT","volume":2899,"amount":2167631.2931,"timestamp":1713965399070},"postHourTrading":{"tag":"盘后","latestPrice":745.69,"preClose":745.69,"latestTime":"19:59 EDT","volume":392941,"amount":293012182.7127,"timestamp":1713916789554},"volumeRatio":0.688575},"requestUrl":"/m/hq/s/LLY/tweets","defaultTab":"tweets","newsList":[{"id":"2430463112","title":"媒体-美国参议院委员会调查 Ozempic 和 Wegovy 成本 - 纽约时报","url":"https://stock-news.laohu8.com/highlight/detail?id=2430463112","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430463112?lang=zh_cn&edition=full","pubTime":"2024-04-25 00:07","pubTimestamp":1713974864,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月24日 - -- 来源链接：  -- 注：路透社未核实此报道，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429511294","title":"礼来下跌1.28%，报736.12美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429511294","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429511294?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:57","pubTimestamp":1713967023,"startTime":"0","endTime":"0","summary":"4月24日，礼来(LLY)盘中下跌1.28%，截至21:57，报736.12美元/股，成交2.21亿美元。财务数据显示，截至2023年12月31日，礼来收入总额341.24亿美元，同比增长19.56%；归母净利润52.4亿美元，同比减少16.08%。大事提醒：4月30日，礼来将于(美东)盘前披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24215740393432.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429358531","title":"礼来6款产品参与胰岛素续标，两款产品高于最高有效申报价","url":"https://stock-news.laohu8.com/highlight/detail?id=2429358531","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2429358531?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:43","pubTimestamp":1713840180,"startTime":"0","endTime":"0","summary":"4月23日，在上海的胰岛素集采续标现场，礼来申报了6款产品，人胰岛素注射液、精蛋白人胰岛素注射液报价31元，高于30元的最高有效申报价。甘精胰岛素注射液报价77.11元，略低于79.2元的最高有效申报价。（澎湃新闻记者 李潇潇）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042310435087a3c3a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042310435087a3c3a6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429897328","title":"礼来将从 Nexus Pharma 收购生产设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2429897328","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429897328?lang=zh_cn&edition=full","pubTime":"2024-04-22 23:41","pubTimestamp":1713800460,"startTime":"0","endTime":"0","summary":"    路透社4月22日 - 礼来  周一表示，它将从Nexus Pharmaceuticals公司收购一家生产注射药物的工厂。礼来预计，位于威斯康星州 Pleasant Prairie 的工厂将于 2025 年底开始生产。上周，美国食品和药物管理局的网站显示 ，由于需求增加，礼来公司大部分剂量的糖尿病药物Mounjaro和减肥药物Zepbound将在今年第二季度限量供应。礼来公司曾表示，预计近期的供应量有限 ，但已发出信号，表示对生产和供应能力的投资将在 2024 年及以后逐步提高药品产量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429912010","title":"礼来盘前涨1% 非洲制药商Aspen助力其减肥药生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2429912010","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2429912010?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:55","pubTimestamp":1713776138,"startTime":"0","endTime":"0","summary":"格隆汇4月22日｜礼来(LLY.US)盘前涨1.06%报734美元。消息面上，由于需求增加，礼来公司糖尿病药物Mounjaro和减肥药物Zepbound的大部分剂量将在今年第二季度限量供应。Aspen首席执行官Stephen Saad表示，将在整个南部非洲分销和推广礼来畅销的糖尿病药物Mounjaro；该公司有能力提高全球最受欢迎的药物的供应。Saad表示，随着时间的推移，阿斯彭也看到了在南非的主要工厂生产胰高血糖素样肽1糖尿病药物和高剂量肥胖药物的机会。\n\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-22/doc-inastanw9922863.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-22/doc-inastanw9922863.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429314919","title":"缓解供应不足 非洲制药商Aspen助力礼来(LLY.US)减肥药生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2429314919","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429314919?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:50","pubTimestamp":1713772200,"startTime":"0","endTime":"0","summary":"非洲最大的制药商Aspen Pharmacare可能有助于缓解世界上最热门的减肥药物日益严重的供应紧张。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240422/20240422154530_69513.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240422/20240422154530_69513.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106423.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429997766","title":"媒体-非洲最大的制药商 Aspen Pharmacare 可帮助缓解肥胖症药品供应紧张问题 - 彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2429997766","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429997766?lang=zh_cn&edition=full","pubTime":"2024-04-22 14:28","pubTimestamp":1713767307,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月22日 - -- 来源链接：  -- 注：路透社未核实此报道，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428259511","title":"印度 Biocon 公司正在开发自己的 Wegovy 版本，明年可能进行临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428259511","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428259511?lang=zh_cn&edition=full","pubTime":"2024-04-19 00:20","pubTimestamp":1713457244,"startTime":"0","endTime":"0","summary":"诺和诺德公司没有立即回应有关各国专利到期的置评请求。礼来公司的糖尿病治疗药物 Mounjaro 正在接受印度药品监管机构的减肥审查。在临床试验中，Wegovy 帮助患者平均减轻了 15%的体重，而 Mounjaro 则平均减轻了 18%。Biocon 公司的诺和诺德 Saxenda 已获得英国批准，这是一种早期的 GLP-1 糖尿病药物，也能帮助人们减轻约 5% 的体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428790561","title":"减肥药开发商 Metsera 获得 2.9 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2428790561","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428790561?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:09","pubTimestamp":1713438543,"startTime":"0","endTime":"0","summary":"Metsera公司由风险投资公司ARCH Venture和投资公司Population Health Partners于2022年成立，目前正在开发基于GLP-1机制和其他生物靶点的治疗肥胖症的注射和口服药物。Meanwell 说，Metsera 的 2.9 亿美元融资是迄今为止从领先的医疗保健投资者银团筹集到的资金总额，包括种子轮和 A 轮融资。Meanwell 拒绝就融资的估值发表评论。Meanwell曾担任The Medicines Company首席执行官近20年，该公司于2019年被瑞士制药商诺华  以97亿美元收购， 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428255323","title":"美国研究综述-建筑商第一资源公司、礼来公司、北方信托公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2428255323","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428255323?lang=zh_cn&edition=full","pubTime":"2024-04-18 15:33","pubTimestamp":1713425634,"startTime":"0","endTime":"0","summary":"    路透社4月18日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括Builders Firstsource、礼来和北方信托。要闻             * Builders Firstsource Inc   ：杰富瑞将目标价从226美元上调至237美元             * 礼来  ：杰富瑞将目标价从885美元上调至895美元             * 北方信托公司  ：杰富瑞将目标价从 101 美元上调至 103 美元 以下是路透社周四报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428587867","title":"需求极度旺盛！FDA：礼来(LLY.US)热门减肥和糖尿病药大部分剂量将在第二季度供不应求","url":"https://stock-news.laohu8.com/highlight/detail?id=2428587867","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428587867?lang=zh_cn&edition=full","pubTime":"2024-04-18 11:32","pubTimestamp":1713411143,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国食品药品监督管理局周三更新的药品短缺数据库显示，随着需求激增，礼来广受欢迎的减肥药Zepbound和糖尿病药物Mounjaro的大部分剂量将在今年第二季度出现供应短缺。最新数据表明，尽管礼来及其主要竞争对手诺和诺德正在努力增加这些治疗药物的产量，但对这类热门减肥和糖尿病药物一直难以满足的需求仍在挤压供应。根据FDA的网站，部分剂量的减肥药Wegovy和糖尿病药物Ozempic也供不应求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104413.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428302266","title":"BUZZ-礼来制药降低睡眠呼吸暂停严重程度后，瑞思迈在澳大利亚证券交易所上市的股票下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2428302266","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428302266?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:12","pubTimestamp":1713402725,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月18日 - ** 在澳大利亚证券交易所上市的瑞思迈  股价下跌多达6.3%，至27.050澳元，将创下自2023年8月7日以来最糟糕的一天--如果跌势得以维持的话。 ** 礼来  周三在 (link)，其减肥药物有助于减少与睡眠呼吸暂停有关的不规则呼吸发作--这是一种常见的睡眠相关疾病。 ** RMD 生产用于治疗睡眠呼吸暂停的设备，因此引发了竞争担忧 ** 股价跌至 3 月 4 日以来最低点 ** 在澳大利亚证券交易所上市的股票在基准指数中跌幅最大 ** 截至上次收盘，今年股价已上涨 13.5","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428275309","title":"潜在首款！礼来Tirzepatide治疗阻塞性睡眠呼吸暂停III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2428275309","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2428275309?lang=zh_cn&edition=full","pubTime":"2024-04-18 08:01","pubTimestamp":1713398507,"startTime":"0","endTime":"0","summary":"4月17日，礼来宣布其GLP-1R/GIPR双重激动剂Tirzepatide用于治疗中度至重度阻塞性睡眠呼吸暂停合并肥胖的III期SURMOUNT-OSA临床试验获得积极结果。此次OSA适应症III期成功意味着Tirzepatide将打开减重之外的又一个市场。研究结果显示，在52周时，Tirzepatide组受试者平均AHI较基线降低了27.4次/小时，而安慰剂组降低了4.8次/小时。SURMOUNT-OSA Study 2评估了Tirzepatide在接受并计划继续进行PAP治疗的中重度OSA合并肥胖成人中的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180804158b31ffd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180804158b31ffd8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428344172","title":"BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后，瑞思迈业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2428344172","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428344172?lang=zh_cn&edition=full","pubTime":"2024-04-17 22:38","pubTimestamp":1713364728,"startTime":"0","endTime":"0","summary":" (更新)    4月17日 - ** 在礼来  的减肥药在睡眠呼吸暂停患者身上的试验取得成功后，CPAP机制造商瑞思迈  的股价下跌3.68%，至178.06美元。** RMD和INSP生产用于治疗睡眠呼吸暂停的医疗设备，睡眠呼吸暂停是一种潜在的严重睡眠障碍，患者呼吸不规律** 礼来公司的减肥药 tirzepatide 有助于减少  阻塞性睡眠呼吸暂停患者的不规则呼吸频率** 券商摩根大通表示，它认为这种药物的减重效果不足以取代 CPAP 或 Inspire，而是可以将替瑞帕肽与这些疗法一起用于治疗 OSA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428719343","title":"美国 FDA 称礼来公司的 Mounjaro 和 Zepbound 大部分剂量限量供应","url":"https://stock-news.laohu8.com/highlight/detail?id=2428719343","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428719343?lang=zh_cn&edition=full","pubTime":"2024-04-17 21:30","pubTimestamp":1713360609,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月17日 - 美国食品和药物管理局网站显示，由于需求增加，礼来公司  糖尿病药物Mounjaro和减肥药物Zepbound的大部分剂量将在今年第二季度限量供应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428317328","title":"大突破！研究显示礼来“减肥神药”有助于缓解睡眠呼吸暂停症状","url":"https://stock-news.laohu8.com/highlight/detail?id=2428317328","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2428317328?lang=zh_cn&edition=full","pubTime":"2024-04-17 20:50","pubTimestamp":1713358218,"startTime":"0","endTime":"0","summary":"减肥神药再添一项适应症，礼来离万亿市值不远了？","market":"hk","thumbnail":"https://static.tigerbbs.com/098638ea5d53d105ccae54cc482b7624","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/098638ea5d53d105ccae54cc482b7624"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712970","is_publish_highlight":true,"gpt_icon":1},{"id":"2428731027","title":"“减肥神药”再迎利好！礼来(LLY.US)tirzepatide在治疗睡眠障碍后期试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2428731027","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428731027?lang=zh_cn&edition=full","pubTime":"2024-04-17 20:50","pubTimestamp":1713358207,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来周三宣布，其减肥疗法tirzepatide在针对肥胖和阻塞性睡眠呼吸暂停患者的两项三期试验中达到了主要目标。在两项试验中，注射药物在52周时使患者体重减轻了近20%，其中70%的试验对象是男性，与女性相比，他们对tirzepatide等肠促胰岛素治疗的反应较差。据了解，凭借FDA批准的GLP-1激动剂，礼来及诺和诺德在新型减肥药市场占据主导地位。截至发稿，礼来盘前涨2.58%，报766.00美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104160.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428314811","title":"BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后，ResMed、Inspire Medical业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2428314811","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428314811?lang=zh_cn&edition=full","pubTime":"2024-04-17 19:52","pubTimestamp":1713354727,"startTime":"0","endTime":"0","summary":"    4月17日 - ** 礼来  减肥药在睡眠呼吸暂停患者试验中获得成功后，瑞思迈  、Inspire Medical  股价盘前下跌** 瑞思迈股价下跌6.6%至172.60美元，Inspire Medical股价下跌7.7%至204.50美元** 在两项后期试验中，礼来公司的减肥药物帮助阻塞性睡眠呼吸暂停患者减少了  不规则呼吸的频率，平均减少幅度高达 63** LLY 股价上涨 1.2%，至 755.72 美元** 瑞思迈和Inspire Medical生产用于治疗睡眠呼吸暂停的医疗设备，睡眠呼吸暂停是一种潜在的严重睡眠障碍，患者的呼吸会反复停止和开始。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428111153","title":"BUZZ-睡眠呼吸暂停患者减肥药试验成功，礼来公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2428111153","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428111153?lang=zh_cn&edition=full","pubTime":"2024-04-17 19:47","pubTimestamp":1713354450,"startTime":"0","endTime":"0","summary":"    4月17日 - ** 制药商礼来  股价盘前上涨1.2%，报755.72美元 ** 该公司称其减肥药在阻塞性睡眠呼吸暂停患者的两项后期试验中取得成功  ** 在两项后期试验中，该药物帮助阻塞性睡眠呼吸暂停患者将不规则呼吸的频率平均降低了63%。** 公司计划从今年年中开始向美国食品和药物管理局 和其他全球监管机构提交数据** 睡眠呼吸暂停是一种潜在的严重睡眠障碍，会导致呼吸不规律** 截至上次收盘，该公司股价年累计上涨约 28","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428249390","title":"礼来减肥药在睡眠呼吸暂停患者试验中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2428249390","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428249390?lang=zh_cn&edition=full","pubTime":"2024-04-17 18:19","pubTimestamp":1713349187,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月17日 - 礼来公司周三表示，该公司的  减肥药在阻塞性睡眠呼吸暂停患者的两项后期试验中取得了成功。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0323},{"period":"3month","weight":0.1767},{"period":"6month","weight":0.3126},{"period":"1year","weight":0.9452},{"period":"ytd","weight":0.2792}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.533333,"avgChangeRate":0.017707},{"month":5,"riseRate":0.409091,"avgChangeRate":0.014113},{"month":6,"riseRate":0.590909,"avgChangeRate":0.021126},{"month":7,"riseRate":0.568182,"avgChangeRate":0.002184},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}